Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
Phase 3 Terminated
102 enrolled
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Phase 1 Terminated
28 enrolled
CPIT001
Phase 1/2 Terminated
46 enrolled 13 charts
NEPI
Phase 1/2 Terminated
1 enrolled
PORTSIDE
Phase 2 Terminated
38 enrolled
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
79 enrolled 24 charts
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Phase 2 Terminated
5 enrolled 13 charts
ATLAS
Phase 2 Terminated
5 enrolled
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Phase 2 Terminated
3 enrolled 7 charts
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Phase 2 Terminated
10 enrolled
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Phase 1/2 Terminated
23 enrolled
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Phase 1 Terminated
67 enrolled
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
Phase 2 Terminated
15 enrolled
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Phase 1/2 Terminated
6 enrolled 11 charts
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Phase 1/2 Terminated
196 enrolled 28 charts
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
Phase 2 Terminated
8 enrolled 11 charts
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase 1/2 Terminated
376 enrolled 56 charts
GVAX Plus Checkpoint Blockade in Neuroblastoma
Phase 1 Terminated
19 enrolled
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Phase 1 Terminated
8 enrolled
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
Phase 1 Terminated
6 enrolled
MODULATE
Phase 1/2 Terminated
2 enrolled 7 charts
PRIMO
Phase 1 Terminated
25 enrolled
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Phase 2 Terminated
4 enrolled 11 charts
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Phase 2 Terminated
12 enrolled 16 charts
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Phase 1 Terminated
11 enrolled
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
Phase 1/2 Terminated
4 enrolled 10 charts
INFLUENCE
Phase 2 Terminated
19 enrolled
QUAD01
Phase 1/2 Terminated
2 enrolled 12 charts
NeAT Glio
Phase 2 Terminated
1 enrolled
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Phase 1 Terminated
1 enrolled
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Phase 2 Terminated
14 enrolled 12 charts
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Phase 1 Terminated
9 enrolled
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Phase 2 Terminated
1 enrolled
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Phase 1 Terminated
22 enrolled 14 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
5 enrolled
NIMBLe
Phase 2 Terminated
4 enrolled 4 charts
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Phase 1 Terminated
2 enrolled 14 charts
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Phase 2 Terminated
9 enrolled 17 charts
PROCLIVITY02
Phase 4 Terminated
29 enrolled 9 charts
FLX475 in Combination With Ipilimumab in Advanced Melanoma
Phase 2 Terminated
6 enrolled 10 charts
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
Phase 2 Terminated
30 enrolled 12 charts
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Phase 1 Terminated
6 enrolled
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Phase 2 Terminated
9 enrolled 13 charts
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Phase 1 Terminated
6 enrolled
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
Phase 1/2 Terminated
15 enrolled 9 charts
Immunotherapy Study for Patients With Stage IV Melanoma
Phase 2 Terminated
47 enrolled 16 charts
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
Phase 2 Terminated
14 enrolled 12 charts